ArticleFrontiers in public health2026
Epidemiological analysis of human papillomavirus and its subtype infections in 36,248 women in Wuhan, China.
Article in Frontiers in public health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Optimization of cultivation strategies for production of recombinant human papillomavirus type 58 major capsid protein L1 in Hansenula polymorpha.Bioresources and bioprocessing · 2026Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: We aimed to analyze the distribution and characteristics of human papillomavirus (HPV) and its subtype infections in women in Wuhan, China, with the objective of providing a reference for the prevention and control of HPV infection and cervical cancer. Methods: We performed a retrospective study of women who visited a gynecology clinic in Wuhan and underwent HPV typing between January 2021 and December 2023. We determined the HPV subtypes by polymerase chain reaction and diversion hybridization and analyzed the epidemiologic characteristics of the women by age and year groups. Results: Among 36,248 women, 8,796 were positive for HPV infection, yielding a prevalence rate of 24.27% and showing an annual increasing trend. Single infection was the main type of HPV infection, accounting for 16.83% of cases, whereas multiple infections accounted for 7.44%. The prevalence rates of high-risk, low-risk, and mixed high- and low-risk HPV infections were 18.59, 2.66, and 3.01%, respectively. The prevalence rates of HPV infection in different age groups showed a bimodal U-shaped distribution, with the first and second peaks observed in the ≤24 year (21.45%) and the 55-64 year (32.45%) groups, respectively. A total of 21 HPV subtypes were identified. The five most common high-risk HPV subtypes were HPV-52, 58, 16, 53, and 51, with prevalence rates of 6.12, 3.66, 3.44, 2.68, and 2.41%, respectively. The three most common low-risk HPV subtypes were HPV-CP8304, 42, and 44, with prevalence rates of 2.17, 1.37, and 0.89%, respectively. In the ≤24 year group, the three most common subtypes were HPV-52, 16, and 58. In the ≥55 year group, the three most common subtypes were HPV-52, 58, and 16. The nine-valent vaccine had a 15.27% HPV genotype coverage rate. The high-risk genotype rate not covered by the vaccine was 10.44%. Conclusion: The HPV prevalence rate among women in Wuhan was higher than that in certain developed cities in China. Among the three existing vaccines, the nine-valent vaccine is more suitable for women in Wuhan. It is necessary to further promote the cervical cancer vaccination program among young women. In addition, cervical cancer screening should be strongly advocated in perimenopausal women. The high frequency of high-risk HPV subtypes that are not covered by existing vaccines highlights the urgent need for new vaccine development based on the HPV epidemiology in the local population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.